File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Entecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis B

TitleEntecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis B
Authors
Issue Date2010
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 2010, v. 51 n. 2, p. 422-430 How to Cite?
AbstractSustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)-022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)-positive CHB. A total of 183 entecavir-treated patients from ETV-022 subsequently enrolled in study ETV-901. We present the results after up to 5 years (240 weeks) of continuous entecavir therapy. The entecavir long-term cohort consists of patients who received ≥1 year of entecavir 0.5 mg in ETV-022 and then entered ETV-901 with a treatment gap ≤35 days. In ETV-901 the entecavir dose was 1.0 mg daily. For patients with samples available at Year 5, proportions with hepatitis B virus (HBV) DNA <300 copies/mL, normal alanine aminotransferase (ALT) levels, HBeAg loss, and HBeAg seroconversion were determined. In all, 146 patients met criteria for inclusion in the entecavir long-term cohort. At Year 5, 94% (88/94) had HBV DNA <300 copies/mL and 80% (78/98) had normal ALT levels. In addition to patients who achieved serologic responses during study ETV-022, 23% (33/141) achieved HBeAg seroconversion and 1.4% (2/145) lost hepatitis B surface antigen (HBsAg) during study ETV-901. Through 5 years, entecavir resistance emerged in one patient. The safety profile of entecavir was consistent with previous reports. Conclusion: Extended therapy with entecavir through 5 years maintained or increased rates of HBV DNA suppression and ALT normalization. Additional patients also achieved HBeAg loss and seroconversion. Entecavir provides sustained viral suppression with minimal resistance during long-term treatment of HBeAgpositive CHB. Copyright © 2009 by the American Association for the Study of Liver Diseases.
Persistent Identifierhttp://hdl.handle.net/10722/163292
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChang, TTen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYoon, SKen_US
dc.contributor.authorLee, SSen_US
dc.contributor.authorCoelho, HSMen_US
dc.contributor.authorCarrilho, FJen_US
dc.contributor.authorPoordad, Fen_US
dc.contributor.authorHalota, Wen_US
dc.contributor.authorHorsmans, Yen_US
dc.contributor.authorTsai, Nen_US
dc.contributor.authorZhang, Hen_US
dc.contributor.authorTenney, DJen_US
dc.contributor.authorTamez, Ren_US
dc.contributor.authorIloeje, Uen_US
dc.date.accessioned2012-09-05T05:29:44Z-
dc.date.available2012-09-05T05:29:44Z-
dc.date.issued2010en_US
dc.identifier.citationHepatology, 2010, v. 51 n. 2, p. 422-430en_US
dc.identifier.issn0270-9139en_US
dc.identifier.urihttp://hdl.handle.net/10722/163292-
dc.description.abstractSustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)-022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)-positive CHB. A total of 183 entecavir-treated patients from ETV-022 subsequently enrolled in study ETV-901. We present the results after up to 5 years (240 weeks) of continuous entecavir therapy. The entecavir long-term cohort consists of patients who received ≥1 year of entecavir 0.5 mg in ETV-022 and then entered ETV-901 with a treatment gap ≤35 days. In ETV-901 the entecavir dose was 1.0 mg daily. For patients with samples available at Year 5, proportions with hepatitis B virus (HBV) DNA <300 copies/mL, normal alanine aminotransferase (ALT) levels, HBeAg loss, and HBeAg seroconversion were determined. In all, 146 patients met criteria for inclusion in the entecavir long-term cohort. At Year 5, 94% (88/94) had HBV DNA <300 copies/mL and 80% (78/98) had normal ALT levels. In addition to patients who achieved serologic responses during study ETV-022, 23% (33/141) achieved HBeAg seroconversion and 1.4% (2/145) lost hepatitis B surface antigen (HBsAg) during study ETV-901. Through 5 years, entecavir resistance emerged in one patient. The safety profile of entecavir was consistent with previous reports. Conclusion: Extended therapy with entecavir through 5 years maintained or increased rates of HBV DNA suppression and ALT normalization. Additional patients also achieved HBeAg loss and seroconversion. Entecavir provides sustained viral suppression with minimal resistance during long-term treatment of HBeAgpositive CHB. Copyright © 2009 by the American Association for the Study of Liver Diseases.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_US
dc.relation.ispartofHepatologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntiviral Agents - Therapeutic Useen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshGuanine - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshHepatitis B E Antigens - Blooden_US
dc.subject.meshHepatitis B, Chronic - Blood - Drug Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshTime Factorsen_US
dc.titleEntecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis Ben_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/hep.23327en_US
dc.identifier.pmid20049753-
dc.identifier.scopuseid_2-s2.0-75449107726en_US
dc.identifier.hkuros181151-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-75449107726&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume51en_US
dc.identifier.issue2en_US
dc.identifier.spage422en_US
dc.identifier.epage430en_US
dc.identifier.isiWOS:000274131200011-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridChang, TT=7404725147en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridYoon, SK=7404036291en_US
dc.identifier.scopusauthoridLee, SS=26643564000en_US
dc.identifier.scopusauthoridCoelho, HSM=35594667700en_US
dc.identifier.scopusauthoridCarrilho, FJ=7007123302en_US
dc.identifier.scopusauthoridPoordad, F=6603753291en_US
dc.identifier.scopusauthoridHalota, W=7003967450en_US
dc.identifier.scopusauthoridHorsmans, Y=7005564253en_US
dc.identifier.scopusauthoridTsai, N=7006824415en_US
dc.identifier.scopusauthoridZhang, H=35742520700en_US
dc.identifier.scopusauthoridTenney, DJ=7006419890en_US
dc.identifier.scopusauthoridTamez, R=25634823500en_US
dc.identifier.scopusauthoridIloeje, U=6602353135en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats